NFKB1 and B-cell chronic lymphocytic leukemia: ND2158 further inhibited TLR agonist-induced NF-κB and STAT3 activity, which play a cooperative role in CLL cell survival [43] and reduced viability, proliferation, adhesion−migration, and cytokine release of CLL cells which were enhanced upon TLR activation.